MS

Michal Silverberg

Managing Director at Novartis Venture Fund -NVF

Greater Boston

VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $5,000,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $7,500,000.00

Skills

Clinical Development
Biotechnology
Pharmaceutical Industry

Education

Investments

Fore Biotherapeutics

Series D

Total Funding: $130M

Twentyeight-Seven Therapeutics

Series A

Total Funding: $80M

Work Experience

novartis venture fund

2017

  • Managing Director

    2017

Takeda Ventures, Inc.

2014 - 2017

  • Senior Partner

    2014 - 2017

Novo Nordisk

2007 - 2013

  • Senior Director Business Development and New Product Commercialization

    2007 - 2013

OSI Pharmaceuticals

2006 - 2007

  • Manager Business Development

    2006 - 2007

MGVS (Multi Gene Vascular Systems)

2003 - 2006

  • VP Business Development and Operation

    2003 - 2006